Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species
Sheng‐Xiong Huang(Zhejiang A & F University), Ben Shen(Brunel University of London), Dawn R. Church(University of Wisconsin–Madison), Jeremy R. Lohman(Scripps Research Institute), George Wilding(The University of Texas MD Anderson Cancer Center), Gudrun Ingenhorst(University of Wisconsin–Madison), Dong Yang(Wuhan University), Yong Huang(Central South University), Tao Liu(Cancer Clinic), Gong-Li Tang(University of Wisconsin–Madison), Bong-Sik Yun(University of Wisconsin–Madison), Hirak S. Basu(The University of Texas Health Science Center at Houston), Ming Ma(Hunan Normal University), Jianhua Ju(Shandong University)
Cited by 51
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels
|Molecular & Cellular Proteomics|2014|419
Cytochromes P450 for natural product biosynthesis in Streptomyces: sequence, structure, and function
|Natural Product Reports|2017|243
Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis
|Nature Communications|2011|201